Belgium’s Convert Pharmaceuticals has secured a €13.6 million grant for initial development efforts on a new targeted chemotherapy drug which could provide benefit in oxygen-deprived cancer cells which older methods have difficulty in treating.
Ook interessant voor je
Reageer